scholarly journals F2. CHANGE IN PROLACTIN AND SEXUAL SIDE EFFECTS IN PATIENTS WITH SCHIZOPHRENIA WHO SWITCHED FROM PALIPERIDONE PALMITATE OR RISPERIDONE LONG-ACTING INJECTION TO ARIPIPRAZOLE LAUROXIL

2019 ◽  
Vol 45 (Supplement_2) ◽  
pp. S255-S255
Author(s):  
Deanna Kelly ◽  
Amy Claxton ◽  
Ilda Bidollari ◽  
Yangchun Du
Keyword(s):  
Side Effects ◽  
Paliperidone Palmitate ◽  
Sexual Side Effects ◽  
Long Acting

scholarly journals Drug information update: paliperidone palmitate for schizophrenia

2013 ◽  
Vol 37 (5) ◽  
pp. 164-166 ◽  
Author(s):  
Abraham M. Nussbaum ◽  
T. Scott Stroup
Keyword(s):  
Side Effects ◽  
Optimal Dose ◽  
Paliperidone Palmitate ◽  
Serum Prolactin ◽  
Sexual Side Effects ◽  
Study Results ◽  
The Us ◽  
Reported Study ◽  
Information Update ◽  
Long Acting

Aims and methodTo review the evidence for the use of paliperidone palmitate for people with schizophrenia and schizophrenia-like illnesses. We searched the Cochrane Schizophrenia Group Specialised Register and contacted the manufacturer of paliperidone palmitate, the US Food and Drug Administration, and the authors of papers that reported study results.ResultsBased on the evidence from five short-term, placebo-controlled studies, paliperidone palmitate is efficacious as an antipsychotic. Its adverse effects are similar to those of the closely related compounds paliperidone and risperidone. Extrapyramidal side-effects, weight gain and tachycardia are more common with paliperidone palmitate than placebo. Paliperidone palmitate was associated with substantial increases in serum prolactin but not with increased sexual side-effects in these studies. In two studies paliperidone palmitate was similar to depot risperidone.Clinical implicationsPaliperidone palmitate is an effective antipsychotic whose optimal dose appears to be between 39 and 234 mg every 4 weeks. We have no data assessing its long-term effectiveness or comparing it with any long-acting injected antipsychotic other than depot risperidone.

scholarly journals Accidental Overdose of Paliperidone Palmitate

2019 ◽  
Vol 2019 ◽  
pp. 1-3 ◽  
Author(s):  
Chiedozie Ojimba ◽  
Ayotomide Oyelakin ◽  
Taher Khandaker
Keyword(s):  
Side Effects ◽  
Plasma Level ◽  
Standard Dose ◽  
Selective Mutism ◽  
Paliperidone Palmitate ◽  
Receptor Sites ◽  
Schizophrenic Patients ◽  
Therapeutic Plasma Level ◽  
Disorganized Speech ◽  
Long Acting

Long-acting injectable (LAI) antipsychotics first introduced in 1960s are useful in the treatment of schizophrenic patients with poor medication adherence due to their maintaining feature of therapeutic plasma level without daily administration. Paliperidone Palmitate is one of such LAI antipsychotic drugs used due to its benefit of maintaining a therapeutic plasma level with four-week interval of injections. We report the case of a 21-year-old male with a history of mental illness that presented with selective mutism, disorganized speech, thought process and behavior, and auditory hallucinations who accidentally received 624 mg Paliperidone Palmitate intramuscularly with no reported side effects after 2 weeks of monitoring and observation. Paliperidone is a D2, 5HT2A receptor antagonist with additional antagonist activity at α-1 and α-2, H-1 receptor sites, and four metabolic pathways identified for its metabolism. Studies have reported adverse effects such as acute dystonia, acute renal failure, and cardiovascular abnormalities with Paliperidone overdose; however there is no reported literature on Paliperidone Palmitate overdose, though there have been reported cases of Paliperidone Palmitate side effects of hypersexuality and angioedema with the standard dose.

scholarly journals Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study

2020 ◽  
Vol 63 (1) ◽  
Author(s):  
Miquel Bioque ◽  
Eduard Parellada ◽  
Clemente García-Rizo ◽  
Sílvia Amoretti ◽  
Adriana Fortea ◽  
...  
Keyword(s):  
Side Effects ◽  
Psychotic Disorders ◽  
Rating Scale ◽  
Symptom Control ◽  
Combined Treatment ◽  
Mirror Image ◽  
Paliperidone Palmitate ◽  
Treatment Resistant ◽  
Image Study ◽  
Long Acting

Abstract Background: Around 30% of patients with schizophrenia are considered treatment resistant (TRS). Only around 40% of TRS patients respond to clozapine. Long acting injectable antipsychotics could be a useful augmentation strategy for nonresponders. Methods: We conducted a multicenter, observational, naturalistic, retrospective, 6-month mirror-image study to evaluate the efficacy and tolerability of clozapine and paliperidone palmitate association in 50 patients with TRS and other psychotic disorders. Clinical outcomes and side effects were systematically assessed. Results: Six months after starting the combined treatment, participants showed a significant relief of symptoms, decreasing the Brief Psychiatric Rating Scale total score from 18.32 ± 7.71 to 7.84 ± 5.16 (p < 0.001). The number of hospitalizations, the length of hospital stays and the number of visits to emergency services also decreased, while an increase of the functionality was observed (Personal and Social Performance total score increased from 46.06 ± 118.7 to 60.86 ± 18.68, p < 0.001). There was also a significant decrease in the number and severity of side effects with the combination therapy, decreasing the Udvalg for Kliniske Undersogelser total score from 10.76 ± 8.04 to 8.82 ± 6.63 (p = 0.004). Conclusions: This study provides the first evidence that combining clozapine with paliperidone palmitate in patients with TRS and other psychotic disorders could be effective and safe, suggesting further research with randomized controlled trials of augmentation strategies for clozapine nonresponder patients. Policy Significance Statement: Patients with psychotic disorders such as schizophrenia show a variable response to antipsychotic treatments. Around 30% of patients are considered treatment resistant, indicated by insufficient symptom control to at least two different drugs. In these resistant cases, clozapine should be indicated, as it has shown to be superior to other options. However, only 40% of patients respond to clozapine, being necessary to establish which treatments could best potentiate clozapine action. Combining clozapine with long acting injectable antipsychotics, and particularly paliperidone palmitate, could be a useful strategy. We conducted a multicenter study of 50 patients with treatment-resistant schizophrenia and other psychotic disorders comparing the efficacy and tolerability in the 6 month-period prior and after starting the clozapine and paliperidone palmitate association. Our study suggests that this combination could be effective and safer, laying the groundwork for future clinical trials with this combination.

Effectiveness of Paliperidone Palmitate Long-Acting Injectable in the Initial Stages of Psychosis: Clinical and Functional Impact

2017 ◽  
Vol 41 (S1) ◽  
pp. S279-S279
Author(s):  
L. Sánchez Blanco ◽  
M. Gómez Revuelta ◽  
V. Gajardo Galán ◽  
M. Juncal Ruíz ◽  
R. Landera Rodríguez ◽  
...  
Keyword(s):  
Side Effects ◽  
Negative Symptoms ◽  
Paliperidone Palmitate ◽  
First Episode ◽  
Adherence To Treatment ◽  
Good Adherence ◽  
Cross Sectional ◽  
Work Activity ◽  
Before And After ◽  
Long Acting

IntroductionAn appropriate early intervention (EI) after the onset of a first episode of psychosis (FEP) is a key factor to prevent relapse, cognitive and functional impairment related to neurotoxicity as it is a critical period in order to get good adherence to treatment. This is the most reported factor linked to relapse. Therefore, interventions focused on getting good adherence to treatment may make the difference in terms of outcome.AimsTo compare relapse rates, symptom severity and level of functionality before and after treatment with Paliperidone Palmitate Long-Acting Injectable (PP-LAI). To analyze prior antipsychotic treatments and side effects registered before and after the introduction of (PP-LAI).Material and methodThis is a cross-sectional descriptive study. We analyzed a sample of 15 patients, recruited from PAFIP (an specialized EI unit) and treated with variable doses of PP-LAI. They all met diagnostic criteria for schizophrenia according to DSM-IV. Clinical and functional data of the two years before and after treatment intoroduction were recorded.ResultsTwenty-seven percent of the patients resumed their work activity or studies and 33% of the patients increased their social activity. Thirteen percent of the patients improved from negative symptoms. Prior to treatment introduction, more than a half of the simple, had suffered one or two relapses. After treatment introduction, 87% did not experience more relapses while 13% experienced another relapse.ConclusionsTreatment with PP-LAI is associated to a recovery of functional abilities, and a trend to clinical stability with high adherence to treatment related to few side effects.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Poster #T229 SEXUAL SIDE EFFECTS IN PATIENTS USING LONG-ACTING DEPOT ANTIPSYCHOTICS

2014 ◽  
Vol 153 ◽  
pp. S370-S371
Author(s):  
Marte Swart ◽  
Marrit de Boer ◽  
Durk Wiersma ◽  
Robert Schoevers ◽  
Henderikus Knegtering
Keyword(s):  
Side Effects ◽  
Sexual Side Effects ◽  
Long Acting ◽  
Depot Antipsychotics

CLINICAL INVESTIGATIONS OF A LONG-ACTING OESTRIOL (POLYOESTRIOL PHOSPHATE)

1961 ◽  
Vol 38 (1) ◽  
pp. 73-87 ◽  
Author(s):  
Christian Lauritzen ◽  
Semih Velibese
Keyword(s):  
Side Effects ◽  
Phosphoric Acid ◽  
Quantitative Data ◽  
Water Soluble ◽  
Cholesterol Concentration ◽  
Experimental Investigations ◽  
Clinical Investigations ◽  
Prolonged Duration ◽  
High Doses ◽  
Long Acting

ABSTRACT A description is given of experimental investigations and preliminary clinical experience with the long-acting oestriol compound polyoestriol phosphate – a water-soluble polymere of oestriol and phosphoric acid. The compound seems to exert all the physiologically important effects of oestriol. Even with high doses the hormone causes no proliferation of the endometrium and no withdrawal bleeding. It has no untoward effect on metabolism. It decreases slightly the cholesterol concentration (to the extent of ⅓–⅕ of the effect produced by long-acting oestradiol esters). The compound has a wide therapeutic range. No side-effects have been observed. Doses of 10 mg or more have a prolonged duration. Additional prolongation of the effect is largely dependent on dosage. To ensure an effect lasting for 4 weeks 40 mg polyoestriol phosphate (corresponding with 30 mg oestriol) is required – an amount which roughly corresponds with physiological quantitative data. The compound, which involves an interesting new principle of prolongation, was most effectively used in the treatment of menopausal symptoms and genital organic disorders. For these indications it can be recommended without reservation.

Sign in / Sign up

Export Citation Format

Share Document